Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 827

Document Document Title
WO/2000/061813A1
A new protein named Tankyrase II is described in this disclosure. Sequences for the human Tankyrase II cDNA and the protein translation product are provided. Also provided are species homologs, muteins, related nucleic acids, peptides, a...  
WO1999064039A9
Disclosed are multibinding compounds which are bradykinin antagonists. The multibinding compounds of this invention contain from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a b...  
WO2000020598A9
This invention relates to compositions and methods which provide protection against, or reduce the severity of toxic shock and septic shock from bacterial infections. More particularly it relates to peptides derived from homologous seque...  
WO2000018910A9
The invention discloses the Moraxella catarrhalis outer membrane protein polypeptide and polypeptides derived therefrom (collectively "OMP21"), nucleotide sequences encoding said OMP21, and antibodies that specifically bind OMP21. Also d...  
WO1999063936A9
Novel multi-binding compounds (agents) which bind endothelin receptors are used to treat disorders affecting the cardiovascular, renal, endocrine and nervous systems in mammals that are mediated by the endothelin receptors, such as conge...  
WO/2000/044776A1
The invention relates to relatively short peptides (termed $g(a) -conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available...  
WO1999064033A9
This invention relates to novel multibinding compounds that bind to the enzyme phosphodiesterase V (PDE V) and modulate its activity. The compounds of this invention comprise 2-10 PDE V modulator (particularly inhibitor) ligands covalent...  
WO1999066944A9
Disclosed are novel multi-binding compounds (agents) which bind cellular receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such cellular receptors thereby modulating the biological proce...  
WO1999064048A9
Disclosed are multibinding compounds which inhibit the enzyme HIV reverse transcriptase, an enzyme which catalyzes the conversion of viral RNA to single stranded DNA. The multibinding compounds of this invention containing from 2 to 10 l...  
WO2000002902A9
This invention provides for polypeptides that have surprising anti-angiogenic activity. These peptides are derived from Saposin B, a previously known protein involved in the hydrolysis of sphingolipids. In addition, methods of treating m...  
WO/2000/042066A1
In a method of purifying whey separated from lactic acid fermentation liquid by electrodialysis wherein said whey contains angiotensin-converting enzyme inhibiting peptides, the improvement which comprises using an anion exchange membran...  
WO1999064035A9
Disclosed are multibinding compounds which are beta 2-adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system...  
WO1999064034A9
The present invention is directed to multibinding compounds which are beta 2 adrenergic receptor agonists and are therefore useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis, and the like. They are...  
WO1999064038A9
Novel multibinding compounds are disclosed. The compounds of the invention comprise from 2-10 ligands covalently connected, each of said ligands being capable of binding to an nAChR receptor, thereby modulating the biological processes/f...  
WO1999063988A9
Disclosed are multibinding compounds which inhibit nitric oxide synthases (NOSs), enzymes which form nitric oxide and L-citrulline from L-arginine. The multibinding compounds of this invention contain from 2 to 10 ligands covalently atta...  
WO1999064031A9
The present invention is directed to multibinding compounds which are beta 2-adrenergic receptor agonists and are therefore useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis, and the like. They are...  
WO1999063933A9
Disclosed are multibinding compounds which are agonists, partial agonists, inverse agonists, partial inverse agonist or antagonists of the GABA receptors, which are involved in neurological disorders. The multibinding compounds of this i...  
WO1999064046A9
Disclosed are novel multi-binding compounds (agents) which bind 5-HT>3< receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such receptors thereby modulating the biological processes/funct...  
WO1999064000A9
Novel multi-binding compounds (agents) which bind neurokinin receptors are used to treat disorders in mammals that are mediated by the neurokinin receptors, such as Parkinson's disease, Alzheimer's disease, depression, anxiety, inflammat...  
WO/2000/020392A1
The invention relates to aryl-substituted propanolamine derivatives and their pharmaceutically acceptable salts and functional derivatives. The invention relates to compounds of formula (I), wherein the radicals have the defined meanings...  
WO1999063983A9
Disclosed are novel multi-binding compounds (agents) which bind to PPAR gamma receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such receptors thereby modulating the biological processes...  
WO1999064047A9
Novel compounds are disclosed, useful as antiviral agents.  
WO1999063929A9
Disclosed are multibinding compounds which inhibit microsomal triglyceride transferase protein (MTP), a protein which mediates the transfer of lipids during the assembly of lipoproteins and related biomolecules. The multibinding compound...  
WO1999064043A9
Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of eac...  
WO1999064054A9
Disclosed are multibinding compounds which inhibit topoisomerases which are essential enzymes in higher encaryotes for DNA replication and repair. The multibinding compounds of this invention containing from 2 to 10 ligands covalently at...  
WO/2000/009144A1
The present invention provides methods and kits for increasing blood flow to ischemic tissue, comprising the administration of an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, ...  
WO/2000/005249A2
The invention provides heteropolymer compositions and peptide compositions, and methods of making and using therapeutic compositions comprising amino acid heteropolymers for treatment of a subject for an autoimmune or an inflammatory dis...  
WO/1999/066934A1
Disclosed are compounds which inhibit $g(b)-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits...  
WO/1999/064042A1
Disclosed are novel multi-binding compounds (agents) which bind alpha-1A adrenergic receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such receptors thereby modulating the biological pro...  
WO/1999/063996A1
Disclosed are multibinding compounds which are agonists, partial agonists, inverse agonists or antagonists of the 5HT¿2? receptors, which are involved in neurological disorders. The multibinding compounds of this invention containing fr...  
WO/1999/064040A1
Novel multibinding compounds are disclosed. The compounds of the invention comprise 2-10 polyene macrolide antibiotic ligands covalently connected, each of said ligands being capable of binding to a ligand binding site in a cellular or v...  
WO/1999/064051A1
Novel multibinding compounds are disclosed. The compounds of the invention comprise from 2-10 ligands covalently connected, each of said ligands being capable of inhibiting bacterial Type II DNA topoisomerase, thereby modulating the biol...  
WO/1999/064052A1
This invention relates to novel multibinding compounds that bind to leukotriene receptors and inhibit their activity. In particular, cysteinal leukotriene receptor antagonists and, most particularly leukotriene D¿4? receptor antagonist ...  
WO/1999/063944A2
Disclosed are novel multi-binding compounds (agents) which bind estrogen receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such receptors thereby modulating the biological processes/func...  
WO/1999/064044A1
Novel multibinding compounds are disclosed. The compounds of the invention comprise from 2-10 ligands covalently connected, each of said ligands being capable of binding to a 5-HT receptor, thereby modulating the biological processes/fun...  
WO/1999/063940A2
Disclosed are multibinding compounds which inhibit H?+¿/K?+¿-ATPase, an enzyme which is involved in the control of acid secretion in the stomach. The multibinding compounds of this invention containing from 2 to 10 ligands covalently a...  
WO/1999/064037A1
Novel multi-binding compounds are disclosed that modulate enzymatic processes. The compounds of the invention comprise from 2-10 ligands covalently connected, each of said ligands being capable of binding to an enzyme, enzyme substrate o...  
WO/1999/063993A1
Disclosed are multibinding compounds which are agonists, partial agonists, inverse agonists or antagonists of the D¿1? receptors, preferably, agonists of the D¿1? receptors, which are involved in neurological disorders. The multibindin...  
WO/1999/063999A1
This invention relates to novel multibinding compounds (agents) that are H1-histamine receptor antagonists and pharmaceutical compositions comprising such compounds. Accordingly, the multibinding compounds and pharmaceutical compositions...  
WO/1999/063930A2
This invention relates to novel multibinding compounds that bind to angiotensin (AT) receptors and modulate their activity. The compounds of this invention comprise 2-10 AT receptor ligands covalently connected by a linker or linkers, wh...  
WO/1999/064053A1
The present invention is directed to multibinding compounds which are $g(b)3-adrenergic receptor agonists and are therefore useful in the treatment and prevention of metabolic disorders such as obesity, diabetes, and the like.  
WO/1999/064032A1
Disclosed are methods for synthesizing large collections of diverse multimeric compounds as well as iterative processes for evaluating key molecular constraints imparting multibinding properties to multimeric compounds. Also disclosed ar...  
WO/1999/055383A2
Novel membrane-forming amphiphilic lipopeptides comprising one or more peptide moieties containing 2-50 aminoacyl residues and one or more hydrocarbon chains containing 5-50 carbon atoms. Such lipopeptides may be used in the formation of...  
WO/1999/054728A2
The ability of a query compound to modulate the biological activity of a receptor in a multicellular organism is predicted on the basis of its interaction with that receptor in the presence of various member of a panel of BioKeys. The Bi...  
WO/1999/050664A1
The invention provides a method based upon the two hybrid system for examining the interactions of nuclear receptors. The invention is additionally directed to compositions for use in the assay and a method of identifying ligands of nucl...  
WO/1999/041608A2
The present invention relates to the finding that cyclin D1 interacts in a ligand-independent fashion with coactivators of the SRC-1 family. The direct interaction of cyclin D1 enhances estrogen receptor (ER) mediated transcription and p...  
WO/1999/037664A1
The present invention relates to peptides that are more potent than or equally potent as the conventional antimicrobial peptides and has strong antimicrobial activities at high salt concentrations.  
WO/1999/037665A1
Peptides which bind to HLA-A29 molecules are disclosed. These molecules satisfy motifs defined by SEQ ID NO: 23, SEQ ID NO: 24 or SEQ ID NO: 25. Also described are minigenes which encode the peptides of the invention as well as their use.  
WO/1999/032498A1
Antibiotic TKR2999 having the following physicochemical properties: (1) the m/z value ([M+H]?+¿) is 971 as determined by FAB mass spectrometry, (2) the molecular formula is C¿44?H¿78?N¿10?O¿14? and the m/z value ([M+H]?+¿) is 971.5...  
WO/1999/015549A2
Peptides of the formula (1) ?N¿TCPPCPXYCPPCPA?C¿ are described wherein X and Y, which may be the same or different, is each a neutral aliphatic L-amino acid residue, and protected and reactive derivatives thereof. The peptides may be u...  

Matches 301 - 350 out of 827